Status:
ACTIVE_NOT_RECRUITING
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Lead Sponsor:
GlaxoSmithKline
Collaborating Sponsors:
Vandage GmbH
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. However, the adverse effects of systemic corticosteroids are one of the most common...
Eligibility Criteria
Inclusion
- Male or female, aged 18 years or older.
- Prevalent diagnosis of an underlying condition.
- At least two years of pre observation period. The same inclusion criteria apply to the matched control group, excluding the initiation of Systemic (cortico)steroids / systemic glucocorticoids (SCS) treatment.
Exclusion
- Have a record of defined SCS-related adverse outcome within two years before index date.
- Have a history of breast cancer and / or tamoxifen prescription
Key Trial Info
Start Date :
July 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2025
Estimated Enrollment :
52000 Patients enrolled
Trial Details
Trial ID
NCT06488703
Start Date
July 1 2024
End Date
July 31 2025
Last Update
June 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rwth Aachen University-Aachen-Germany-C
Germany, Germany